Details of the Drug

General Information of Drug (ID: DMUWXEB)

Drug Name
QPI-1007
Synonyms SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Ischemic optic neuropathy 9C40.4 Phase 3 [1]
Non-arteritic anterior ischemic optic neuropathy 9C40.40 Phase 3 [2]
Glaucoma/ocular hypertension 9C61 Phase 2/3 [3]
Drug Type
siRNA drug
Cross-matching ID
TTD ID
D06ZFV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Caspase 2 messenger RNA (CASP2 mRNA) TT12VNG CASP2_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02341560) Phase II/III, Randomized, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION). U.S. National Institutes of Health.
4 Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66.